{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T15:30:39Z","timestamp":1748446239846,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Magnesium changes are common in myocardial infarction (MI) complicated with left ventricular systolic dysfunction (LVSD) and\/or heart failure (HF). The relation between serum magnesium and clinical outcomes is insufficiently elucidated in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The EPHESUS trial randomized 6632 patients to either eplerenone or placebo. Hypomagnesemia and hypermagnesemia were defined as a serum magnesium &amp;lt;0.66 and &amp;gt;1.10\u2009mmol\/L, respectively. Linear mixed models and time-dependent Cox regression analysis were used to determine the effect of eplerenone on magnesium changes and the prognostic importance of magnesium. The co-primary outcomes were all-cause mortality and a composite of cardiovascular (CV) mortality and CV hospitalization. A total of 5371 patients had a post-baseline magnesium measurement. At baseline, 231 (4.3%) patients had hypomagnesemia and 271 (5.0%) patients had hypermagnesemia. During a median follow-up of 16\u2009months, 682 (13%) developed hypomagnesemia and 512 (9.5%) hypermagnesemia. Eplerenone treatment did not result in a different magnesium level during follow-up (P\u2009=\u20090.14). After covariate adjustment hypo- and hypermagnesemia were not associated with a higher risk of CV events. Magnesium levels did not modulate the effect of a high potassium (&amp;gt;5\u2009mmol\/L) or low potassium (&amp;lt;4\u2009mmol\/L) on the clinical outcome. Baseline magnesium levels did not influence the treatment effect of eplerenone (P-interaction &amp;gt; 0.1 for all primary and secondary endpoints).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with MI complicated by LVSD or HF, magnesium alterations were not associated with clinical outcomes nor did they influence the effect of eplerenone. Serum magnesium did not modulate the effect of potassium changes on clinical outcome or the treatment effect of eplerenone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                  <jats:p>NCT00232180.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuab111","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T12:23:43Z","timestamp":1636115023000},"page":"148-159","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-2113","authenticated-orcid":false,"given":"Pieter","family":"Martens","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost Limburg, Genk, Belgium"},{"name":"Department of Medicine and Life Sciences, University Hasselt, Hasselt, Belgium"},{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques-1433, France"},{"name":"Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, Nancy, France"}]},{"given":"John","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}]},{"given":"Paula","family":"Abreu","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}]},{"given":"Martijn","family":"Busselen","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost Limburg, Genk, Belgium"},{"name":"Department of Medicine and Life Sciences, University Hasselt, Hasselt, Belgium"}]},{"given":"Wai Hong Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Saarland University, Saarbr\u00fccken, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques-1433, France"},{"name":"Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, Nancy, France"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques-1433, France"},{"name":"Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, Nancy, France"}]}],"member":"286","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"2022020904571849200_zuab111-B1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/07315724.1994.10718432","article-title":"Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review)","volume":"13","author":"Seelig","year":"1994","journal-title":"J Am Coll Nutr"},{"key":"2022020904571849200_zuab111-B2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.jacc.2017.03.579","article-title":"Serum magnesium levels and in-hospital mortality in acute myocardial infarction","volume":"69","author":"Shafiq","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022020904571849200_zuab111-B3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ije\/28.4.645","article-title":"Serum magnesium and ischaemic heart disease: findings from a national sample of US adults","volume":"28","author":"Ford","year":"1999","journal-title":"Int J Epidemiol"},{"key":"2022020904571849200_zuab111-B4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0008-6363(98)00200-4","article-title":"Regional electrophysiological effects of hypokalaemia, hypomagnesaemia and hyponatraemia in isolated rabbit hearts in normal and ischaemic conditions","volume":"40","author":"Wolk","year":"1998","journal-title":"Cardiovasc Res"},{"key":"2022020904571849200_zuab111-B5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2022020904571849200_zuab111-B6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.0954-6820.1980.tb09676.x","article-title":"Serum magnesium in acute myocardial infarction. Relation to arrhythmias","volume":"207","author":"Dyckner","year":"1980","journal-title":"Acta Med Scand"},{"key":"2022020904571849200_zuab111-B7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/clc.4960100610","article-title":"Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study","volume":"10","author":"Rasmussen","year":"1987","journal-title":"Clin Cardiol"},{"key":"2022020904571849200_zuab111-B8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/clc.4960160607","article-title":"Ventricular arrhythmias late after myocardial infarction are related to hypomagnesemia and magnesium loss: preliminary trial of corrective therapy","volume":"16","author":"Ceremuzynski","year":"1993","journal-title":"Clin Cardiol"},{"key":"2022020904571849200_zuab111-B9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0140-6736(92)91828-V","article-title":"Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)","volume":"339","author":"Woods","year":"1992","journal-title":"Lancet"},{"key":"2022020904571849200_zuab111-B10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(02)11278-5","article-title":"Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"2022020904571849200_zuab111-B11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0735-1097(93)90095-I","article-title":"Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study","volume":"21","author":"Eichhorn","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2022020904571849200_zuab111-B12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0735-1097(10)80329-8","article-title":"Prognostic importance of the serum magnesium concentration in patients with congestive heart failure","volume":"16","author":"Gottlieb","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"2022020904571849200_zuab111-B13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"journal-title":"Clin Res Cardiol","article-title":"Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial","author":"Martens","key":"2022020904571849200_zuab111-B14"},{"key":"2022020904571849200_zuab111-B15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pds.4636","article-title":"Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population","volume":"27","author":"Kieboom","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022020904571849200_zuab111-B16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/nu10091202","article-title":"Challenges in the diagnosis of magnesium status","volume":"10","author":"Workinger","year":"2018","journal-title":"Nutrients"},{"key":"2022020904571849200_zuab111-B17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"2022020904571849200_zuab111-B18","doi-asserted-by":"crossref","first-page":"e5406","DOI":"10.1097\/MD.0000000000005406","article-title":"The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta-analysis","volume":"95","author":"Angkananard","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"2022020904571849200_zuab111-B19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.mayocp.2015.04.023","article-title":"Dysmagnesemia in hospitalized patients: prevalence and prognostic importance","volume":"90","author":"Cheungpasitporn","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2022020904571849200_zuab111-B20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"2022020904571849200_zuab111-B21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/0735-1097(92)90177-O","article-title":"Myocardial magnesium depletion associated with prolonged hypomagnesemia: a longitudinal study in heart transplant recipients","volume":"20","author":"Millane","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2022020904571849200_zuab111-B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"}],"container-title":["European Heart Journal. Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/2\/148\/42437125\/zuab111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/2\/148\/42437125\/zuab111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T05:20:00Z","timestamp":1644384000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/11\/2\/148\/6503598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,11]]},"published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuab111","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"type":"print","value":"2048-8726"},{"type":"electronic","value":"2048-8734"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2022,1,11]]}}}